20-F: Black Titan Completes Merger, Eyes APAC HCM & Crypto Growth

Sentiment:

Annual Report 28 November 2025 5:16 PM

📋All filings for Bitech Technologies CORP

Black Titan Corporation has successfully completed its merger with TalenTec Sdn. Bhd. and Titan Pharmaceuticals Inc., listing on Nasdaq and outlining ambitious growth strategies in human capital management and cryptocurrency.

Delay expectedTalenTec's HCM solution project deliverables are exposed to unexpected delays or interruptions caused by operational factors, accidents, and natural disasters beyond its control.The development of a new SaaS HCM application for the hospitality industry is in 'very early stages,' and there is no assurance that the project will be successfully concluded as scheduled (intended for end of calendar 2025) or at all.

Capital raiseBlack Titan entered into a Subscription Agreement with ARC Group Limited for the purchase of up to $6,000,000 of Series A convertible preferred shares, with $5,500,000 drawn down on October 1, 2025.Titan Pharmaceuticals Inc. completed a private placement with Blue Harbor Asset Management L.L.C-FZ in April 2025, issuing 100,000 shares of Series B Preferred Stock for $1,000,000.Titan Pharmaceuticals Inc. completed an additional private placement with Blue Harbor Asset Management L.L.C-FZ in June 2025, issuing 60,000 shares of Series C Convertible Preferred Stock for $600,000.

Better than expectedTalenTec, the primary operating entity of the combined company, reported a 26.3% increase in total revenues for fiscal year 2025, reaching $2,683,126.TalenTec's net income grew to $209,911 in fiscal year 2025 from $153,227 in the previous year.TalenTec achieved a 100% subscription renewal rate for its existing customers in both fiscal years 2024 and 2025, indicating strong customer satisfaction and recurring revenue.

Summary

Black Titan Corporation (PubCo) completed its merger with TalenTec Sdn. Bhd. and Titan Pharmaceuticals Inc. on October 1, 2025, with Black Titan's ordinary shares commencing trading on Nasdaq under the ticker BTTC on October 2, 2025.
TalenTec, the accounting acquirer, reported total revenues of $2,683,126 for the fiscal year ended July 31, 2025, a 26.3% increase from $2,124,496 in fiscal year 2024.
TalenTec's net income for fiscal year 2025 was $209,911, up from $153,227 in fiscal year 2024.
Black Titan incurred a net loss of $163,173 for the fiscal year ended July 31, 2025, and had a working capital deficit of $167,120, relying on related-party support and anticipated financing.
The company announced plans on October 6, 2025, to pursue long-term strategic crypto initiatives, including direct coin acquisitions, mining, and fintech-related mergers and acquisitions.
TalenTec shareholders and holders of TTNP Series AA Preferred Stock collectively own 68.56% of the 7,723,620 Black Titan Ordinary Shares outstanding post-merger.
Material weaknesses in internal control over financial reporting were identified for TalenTec for fiscal years 2024 and 2023, related to a lack of GAAP/SEC reporting knowledge and IT general controls, with remediation plans underway.
Black Titan secured a PIPE investment of up to $6,000,000 in Series A convertible preferred shares from ARC Group Limited, with $5,500,000 drawn down on October 1, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. The successful merger and Nasdaq listing are significant milestones. TalenTec, the core operating business, shows strong revenue and net income growth, high customer retention, and clear strategic plans for expansion and cloud adoption. However, the new parent company (Black Titan) has initial losses and working capital deficits, and there are numerous risks related to integration, intense competition, reliance on third-party vendors, and identified material weaknesses in internal controls. The new crypto strategy introduces additional, potentially high-risk, ventures.

Positives

TalenTec achieved significant revenue growth of 26.3% to $2,683,126 in fiscal year 2025, driven by increases across all service categories.
Net income for TalenTec increased to $209,911 in fiscal year 2025 from $153,227 in the prior year.
TalenTec maintained a 100% subscription renewal rate for existing customers in both fiscal years 2024 and 2025.
The successful completion of the merger and Nasdaq listing provides a platform for future growth and access to capital markets.
TalenTec boasts strong, long-term customer relationships, including a regulatory authority in Malaysia that has been a client for over 25 years.
Strategic plans include expanding operations in high-growth APAC markets like Singapore, Indonesia, and the Philippines, and developing new cloud-based HCM solutions.
The company has a seasoned team of 30 in-house consultants with multiple product certifications, providing a competitive edge in service delivery.

Negatives

Black Titan Corporation incurred a net loss of $163,173 and had a working capital deficit of $167,120 for the fiscal year ended July 31, 2025, with no revenue-generating activities since inception.
TalenTec had projected working capital deficits for fiscal years 2024 through 2026 prior to an equity investment, indicating potential liquidity challenges.
A significant portion of TalenTec's revenue (approximately 34% in fiscal year 2025) is dependent on three key customers, posing a concentration risk.
Material weaknesses were identified in TalenTec's internal control over financial reporting for fiscal years 2024 and 2023, requiring remediation efforts.
TalenTec's management team has limited experience managing a public company, which could strain resources and attention.
The company will incur increased legal, accounting, and other expenses as a public company.
No dividends are anticipated in the foreseeable future, meaning investors must rely on share price appreciation for returns.
Significant payments were made for warrant repurchases and a settlement with Armistice Capital, totaling over $3 million in cash and shares.

Risks

Dependency on licenses, reseller contracts, and distribution agreements with third-party software vendors (e.g., Oracle, Dayforce), with changes or termination posing a material adverse effect.
Intense competition from other HCM solutions providers and vendors, potentially leading to reduced sales, margins, or market acceptance.
Limited target market due to the high cost of HCM solutions, primarily catering to large organizations with substantial HR budgets.
Fluctuations in revenue, profit, and operating cash flow due to the project-based and contract-based nature of the business and timing of delivery.
Exposure to credit risk and default payment by customers, which could adversely affect operating cash flows and financial results.
Borrowing risks and restrictive covenants in credit facilities, including limitations on dividend distributions and potential for events of default.
Foreign exchange transaction risks due to operations and transactions in multiple currencies (MYR, SGD), impacting profitability.
HCM solution project deliverables are exposed to unexpected delays or interruptions caused by operational factors, accidents, and natural disasters.
Potential claims for liquidated damages from customers for delays or failures in providing services, increasing operating costs.
Dependence on growth in market acceptance of the digitalization of human resources processes and related services.
Inability to rapidly grow the sales force, which could hinder business growth at anticipated rates.
Failure to maintain or enhance reputation or brand recognition could harm the business.
Inability to successfully implement business strategies, including regional expansion and new product development, potentially leading to adverse financial performance.
Most customer contracts are short-term, requiring continuous securing of new contracts and renewals to maintain business.
Exposure to economic, political, legal, and regulatory environments in operating countries (Malaysia, Singapore, Indonesia, Philippines), which could adversely affect business.
Inadequate insurance coverage for all potential losses or liabilities.
Changes in laws and regulations related to the Internet or changes in the Internet infrastructure itself may diminish demand for solutions.
Volatility in the financial and economic environment could harm the business.
Security breaches in third-party HCM solutions (Oracle PeopleSoft, Dayforce HCM, SunFish WorkPlaze HR, MiHCM Cloud) could indirectly affect reputation.
Privacy concerns, evolving regulation of cloud computing, and cross-border data transfer may reduce adoption of solutions and increase compliance challenges.
Utilization of open-source software (e.g., Sunfish Workplaze HR) carries risks related to license compliance and potential requirements to release proprietary source code.
TalenTec's management team has limited experience managing a public company, potentially leading to challenges in compliance and investor relations.
Risk of delisting from Nasdaq if the company cannot comply with continued listing standards.
Difficulties in protecting shareholder interests and limited ability to protect rights through U.S. courts due to incorporation under Cayman Islands law.
Potential classification as a passive foreign investment company (PFIC) for U.S. federal income tax purposes, leading to adverse tax consequences for U.S. Holders.
Risk that the IRS may not agree that Black Titan should be treated as a non-U.S. corporation for U.S. federal income tax purposes, leading to substantial U.S. tax liability.

Future Outlook

Black Titan plans to expand its market share by continuing to add to its Human Capital Management (HCM) product offerings and expanding operations to other countries in the Southeast Asia Pacific region, specifically Indonesia and the Philippines. The company is participating in the development of a SaaS HCM application for the hospitality industry, with a beta version scheduled for rollout in the second fiscal quarter of 2026. Management anticipates increased sales and marketing expenses due to digitalization efforts. Additionally, Black Titan intends to seek long-term strategic crypto initiatives, exploring direct coin acquisitions, mining, and fintech-related mergers and acquisitions.

Management Comments

Our vision is to be the go-to human resources consulting group in our markets for companies seeking to improve their businesses by adopting more efficient HCM solutions.
Our mission is to be recognized as a leading provider of on-premises and cloud-based SaaS HCM software solutions from world leading software companies, providing ongoing support and product upgrades, complemented with superior consulting services in the Asia Pacific region.
We believe that our ability to support the different solutions that we sources, with our on-staff consultants, gives the Company a competitive edge that the Company believes other HCM service providers do not offer.
Management aims to position the Company not just as a software reseller, but, through long-term relationships, as a strategic partner that enhances human resource capabilities through technology and innovative solutions.
Management expects Black Titan to continue relying on related-party support and anticipated Transaction Financing until completion of the Business Combination.
Management expects that financial support commitment from its shareholder will resolve these uncertainties regarding Black Titan's ability to continue as a going concern.

Industry Context

The Human Capital Management (HCM) software market in APAC is projected for significant growth, from $9.03 billion in 2025 to $18.18 billion by 2030, at a CAGR of 15.02%. This growth is driven by regulatory support for digitalization from the Malaysian government, increasing demand for unified HR solutions, and the adoption of advanced technologies like AI. By 2025, 60% of midmarket and large enterprises are expected to invest in cloud-deployed HCM suites. TalenTec's strategy to introduce and market cloud-based solutions and its use of AI in resold software aligns with these trends. Key competitors in Southeast Asia include Ramssol Group Bhd, Payroll2U, and Kakitangan.com, offering similar HCM and IT staff augmentation services.

Comparison to Industry Standards

The APAC HCM software market is projected to grow at a CAGR of 15.02% from $9.03 billion in 2025 to $18.18 billion by 2030. TalenTec's revenue growth of 26.3% in FY2025 suggests it is outperforming the broader market growth rate, indicating strong market penetration or expansion.
Industry trends indicate that by 2025, 60% of midmarket and large enterprise organizations will have invested in a cloud-deployed HCM suite. TalenTec's strategic shift towards cloud-based solutions and its 100% SaaS subscription renewal rate demonstrate alignment with and successful capture of this market shift.
78% of HR managers anticipate harnessing Artificial Intelligence (AI) in at least one HR process within the next two years. TalenTec's offerings, which include Dayforce Co-Pilot (Microsoft AI), MiHCM SmartAssist (Microsoft AI), and SunFish Workplaze HR AI Assistant (OpenAI technology), position it to meet this evolving demand, comparable to competitors who also offer advanced digitalization solutions.
Competitors like Ramssol Group Bhd (RAMS Solution Sdn Bhd) specialize in Oracle HCM and Campus applications, including Oracle Fusion HCM Cloud. TalenTec also distributes Oracle PeopleSoft HCM/Financials and is expanding its cloud offerings, indicating direct competition in similar product segments.
Payroll2U, a Singapore-headquartered competitor, provides payroll outsourcing and proprietary SaaS solutions (smartPAY). TalenTec's focus on comprehensive HCM solutions, including SaaS subscriptions, places it in direct competition with such specialized providers, though TalenTec emphasizes its multi-vendor approach.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Co-Chief Executive Officer and Director (Black Titan)	NA	Chay Weei Jye	2025-09-18	Appointment following the Business Combination; previously CEO of Titan Pharmaceuticals Inc.
Co-Chief Executive Officer (Black Titan)	NA	Shang Ju (Czhang) Lin	2025-11-10	Appointment following the Business Combination.
Chief Financial Officer and Director (Black Titan)	NA	Brynner Chiam	2025-08-21	Appointment following the Business Combination; previously sole director and principal executive officer of Black Titan, and acting principal executive/financial officer of Titan Pharmaceuticals Inc.
Independent Director (Black Titan)	NA	Francisco Osvaldo Flores Garcia	2025-10-01	Appointment following the Business Combination.
Independent Director (Black Titan)	NA	Firdauz Edmin Bin Mokhtar	2025-10-01	Appointment following the Business Combination; previously appointed independent director of Titan Pharmaceuticals Inc.
Independent Director (Black Titan)	NA	Gabriel Loh	2025-10-01	Appointment following the Business Combination; previously appointed independent director of Titan Pharmaceuticals Inc.
Independent Director (Black Titan)	NA	Avraham Ben-Tzvi	2025-10-01	Appointment following the Business Combination; previously served on Titan Pharmaceuticals Inc.'s Board.
Chief Executive Officer and Chairman of the Board (Titan Pharmaceuticals Inc.)	Seow Gim Shen	NA	2024-10-24	Resignation for personal reasons.
Chief Executive Officer (Titan Pharmaceuticals Inc.)	David Lazar	NA	2024-04-02	Resignation.
President and Chief Operating Officer and Board Member (Titan Pharmaceuticals Inc.)	Kate Beebe DeVarney, Ph.D.	NA	2024-04-02	Resignation.
Board Member (Titan Pharmaceuticals Inc.)	Eric Greenberg	NA	2024-04-02	Resignation.
Board Member (Titan Pharmaceuticals Inc.)	Matthew C. McMurdo	NA	2024-04-02	Resignation.
Board Member (Titan Pharmaceuticals Inc.)	David Natan	NA	2024-04-02	Resignation.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Foreign Private Issuer Status	Black Titan is an exempted company incorporated under Cayman Islands law and qualifies as a foreign private issuer, exempting it from certain Nasdaq corporate governance standards (e.g., majority independent board, independent compensation/nominating committees).	2025-10-01	Provides less protection to shareholders compared to U.S. domestic issuers, as fewer board members may exercise independent judgment and board oversight of management may decrease.
Board Composition	The Board of Directors consists of six directors, with four qualifying as independent under Nasdaq guidelines.	2025-10-01	Meets the minimum requirements for a foreign private issuer, but does not adhere to the majority independent director rule for U.S. domestic issuers.
Audit Committee Establishment	A separately standing Audit Committee has been established, consisting of Firdauz Edmin Bin Mokhtar (Chair), Francisco Osvaldo Flores Garca, and Gabriel Loh. All members are independent, and Mr. Mokhtar is designated as an audit committee financial expert.	2025-10-01	Enhances financial oversight and compliance with SEC and Nasdaq requirements for audit committees.
Nominating and Corporate Governance Committee Establishment	A Nominating and Corporate Governance Committee has been established, consisting of Francisco Osvaldo Flores Garca (Chair), Avraham Ben-Tzvi, and Firdauz Edmin Bin Mokhtar. All members are independent.	2025-10-01	Formalizes the process for director nominations and oversight of corporate governance guidelines, aligning with best practices.
Compensation Committee Establishment	A Compensation Committee has been established, consisting of Francisco Osvaldo Flores Garca (Chair) and Firdauz Edmin Bin Mokhtar. Both members are independent.	2025-10-01	Provides independent oversight of executive compensation, incentive plans, and related policies.
Code of Ethics Adoption	A Code of Ethics that applies to all executive officers, directors, and employees has been adopted.	2025-11-28	Establishes ethical standards and promotes compliance with legal and regulatory requirements across the organization.
Insider Trading Policy Adoption	An Insider Trading Policy has been adopted to prevent insider trading violations by directors, officers, employees, and related individuals.	2025-11-28	Mitigates legal and reputational risks associated with insider trading and promotes fair dealing in company securities.
Compensation Recovery Policy (Clawback) Adoption	A Compensation Recovery Policy has been adopted to recover erroneously awarded compensation from covered persons in the event of a financial restatement, in accordance with SEC and Nasdaq rules.	2025-11-28	Enhances accountability for executive compensation and aligns with regulatory requirements for clawback provisions.
Internal Control Weaknesses (TalenTec)	Material weaknesses in internal control over financial reporting were identified for TalenTec for fiscal years 2024 and 2023, specifically regarding lack of GAAP/SEC reporting knowledge and IT general controls.	NA	Requires significant management attention and resources for remediation, posing a risk to accurate financial reporting and investor confidence if not effectively addressed.

Legal Proceedings

Black Titan Corporation is not currently a party to any legal proceedings the outcome of which would individually or in the aggregate have a material adverse effect on its business, financial condition, or results of operations.
Titan Pharmaceuticals Inc. had a legal proceeding initiated in 2020 by a former employee alleging wrongful termination, retaliation, and other claims; however, Fedson, Inc. assumed all liabilities related to this claim in September 2023 as part of an asset purchase agreement.

Related Party Transactions

Black Titan Corporation incurred administrative expenses charged by a related party, amounting to US$3,947 for the period from July 11, 2024, to July 31, 2024, and US$163,173 for the year ended July 31, 2025.
Black Titan Corporation relies on related-party support and anticipated Transaction Financing to fund its operations, with a shareholder (Mr. Choong Choon Hau) committed to funding working capital.
TalenTec Sdn. Bhd. had transactions with HO SAY SAN (shareholder and director) for borrowings and repayments.
TalenTec Sdn. Bhd. had transactions with The Sire Group Ltd. (controlled by a former significant shareholder) for payment of professional fees on behalf of the company, amounting to $355,450 in 2024.
HO SAY SAN and CHOO YEOW (shareholders and directors of TalenTec) provided joint and several guarantees for TalenTec's bank borrowings.
Titan Pharmaceuticals Inc. made payments related to legal and consulting fees of approximately $7,538 (nine months ended September 30, 2025) and $11,138 (nine months ended September 30, 2024) to a law firm operated by one of its Board members.
Titan Pharmaceuticals Inc. had a receivable balance of approximately $232,000 from Black Titan as of September 30, 2025, including advances of approximately $170,000 made during the nine months ended September 30, 2025.
Titan Pharmaceuticals Inc. received $500,000 in funding from Choong Choon Hau via a convertible promissory note in August 2023, which was converted into 54,132 shares of common stock in March 2024.

Stakeholder Impact

Shareholders: Potential for value creation through growth in the HCM market and new crypto initiatives, but also exposed to risks from integration, competition, and the inherent volatility of new ventures. Dilution from capital raises is a factor, and less protection is afforded due to foreign private issuer status.
Employees: TalenTec's continued success and expansion plans are dependent on attracting, training, and retaining competent and skilled consultants and staff, indicating potential for job growth and development opportunities.
Customers: The company's focus on customer-oriented services, highly configured solutions, and strong technical support aims to enhance customer satisfaction and retention, but project delays or dissatisfaction could negatively impact relationships.
Creditors: Black Titan's reliance on shareholder financial support to address working capital deficits and going concern uncertainties highlights a dependency that creditors should monitor. TalenTec's exposure to credit risk from customers could affect its ability to meet obligations.
Suppliers/Vendors: The company's business model relies heavily on licenses, reseller contracts, and distribution agreements with third-party software vendors, making these relationships critical for continued operations and product offerings.

Next Steps

Continue to add to the suite of HCM solutions, including participating in the development of a SaaS HCM application for the hospitality industry, with a beta version rollout scheduled for Q2 2026.
Expand operations in Singapore, Indonesia, and extend into the Philippines and Vietnam, contingent on successful discussions with a major global U.S.-based HCM vendor and completion of SaaS solution development.
Continue to build and develop strong customer relationships, enhance customer retention, and encourage referrals.
Transition existing on-premises clients to hybrid and ultimately cloud-based solutions over the next several years.
Rapidly grow the direct sales force to raise awareness and acquire new customers.
Implement and maintain an effective system of internal controls to address identified material weaknesses in financial reporting and IT general controls.
Seek long-term strategic crypto initiatives, including direct coin acquisitions, mining, and fintech-related mergers and acquisitions.

Key Dates

Date	Description
2024-07-11	Black Titan Corporation incorporated in the Cayman Islands.
2024-08-19	Merger and Contribution and Share Exchange Agreement signed between PubCo, Merger Sub, and TalenTec.
2024-09-26	TalenTec changed its name to TalenTec Sdn. Bhd. from KE. Sdn. Bhd.
2024-10-02	Black Titan confidentially filed a joint proxy statement/prospectus with the SEC.
2024-10-24	Seow Gim Shen notified the Board of Directors of Titan Pharmaceuticals Inc. of his decision to resign as Chief Executive Officer and Chairman of the Board.
2024-11-06	Brynner Chiam appointed acting principal executive officer and acting principal financial officer of Titan Pharmaceuticals Inc.
2024-12-02	Mr. Chay Weei Jye appointed Chief Executive Officer of Titan Pharmaceuticals Inc.
2024-12	Mr. Seow sold all his shares in TalenTec to Danny Vincent Dass and all his shares in The Sire Group Ltd. to Jeffrey Chung.
2025-01-03	Titan Pharmaceuticals Inc. received a notice from Nasdaq Listing Qualifications Staff regarding noncompliance with Listing Rule 5620 (failure to hold annual shareholder meeting).
2025-03-20	Titan Pharmaceuticals Inc. entered into an Employment Agreement with Chay Weei Jye.
2025-03-26	Titan Pharmaceuticals Inc. received a notice from Nasdaq Listing Qualifications staff regarding noncompliance with Listing Rule 5550(b)(1) (stockholders equity).
2025-03-27	Gabriel Loh appointed as an independent director of Titan Pharmaceuticals Inc.
2025-03-29	Titan Pharmaceuticals Inc. entered into a Securities Purchase Agreement with Blue Harbor Asset Management L.L.C-FZ for the issuance of Series B Preferred Stock.
2025-04-11	Titan Pharmaceuticals Inc. completed a private placement transaction with Blue Harbor Asset Management L.L.C-FZ, issuing 100,000 shares of Series B Preferred Stock for $1,000,000.
2025-05-13	Titan Pharmaceuticals Inc. received Notices of Conversion from Sire and Blue Harbor Asset Management L.L.C-FZ for preferred stock.
2025-05-30	Titan Pharmaceuticals Inc. issued 150,087 shares of common stock to Sire and 265,913 shares of common stock to Blue Harbor Asset Management L.L.C-FZ upon conversion of preferred stock.
2025-06-02	Amended joint proxy/registration statement on Form F-4 publicly filed by Black Titan.
2025-06-16	Titan Pharmaceuticals Inc. conducted its 2025 Annual Meeting of Stockholders.
2025-06-20	Black Titan Corporation entered into a subscription agreement with ARC Group Limited for the purchase of up to $4,000,000 of Series A convertible preferred shares. Titan Pharmaceuticals Inc. received a notice from Nasdaq confirming compliance with the annual meeting requirement.
2025-06-24	Titan Pharmaceuticals Inc. completed an additional private placement with Blue Harbor Asset Management L.L.C-FZ, issuing 60,000 shares of Series C Convertible Preferred Stock for $600,000.
2025-07-21	The SEC declared the Form F-4 effective.
2025-07-22	Titan Pharmaceuticals Inc. filed a definitive proxy statement on Schedule 14A for a special meeting of stockholders on August 26, 2025.
2025-07-25	Share Exchange Agreement dated.
2025-07-31	Fiscal year end for Black Titan Corporation and TalenTec Sdn. Bhd.
2025-08-21	Brynner Chiam served as Chief Financial Officer and director of Black Titan. The SPA was amended to increase the amount of Series A Preferred Shares to be purchased to up to $6,000,000.
2025-08-22	Titan Pharmaceuticals Inc. received a Notice of Conversion from Blue Harbor Asset Management L.L.C-FZ for 20,227 shares of Series B Preferred Stock, resulting in the issuance of 67,420 shares of common stock.
2025-08-26	The Merger Agreement was approved by the stockholders of Titan Pharmaceuticals Inc. and TalenTec Sdn. Bhd.
2025-09-17	Titan Pharmaceuticals Inc. received a letter from Nasdaq confirming compliance with the Equity Rule.
2025-10-01	The Business Combination was consummated. Black Titan submitted a Drawdown Notice for $5,500,000, resulting in the issuance of 5,500 Series A Preferred Shares. Registration Rights Agreement dated. Francisco Osvaldo Flores Garca, Firdauz Edmin Bin Mokhtar, Gabriel Loh, and Avraham Ben-Tzvi served as directors.
2025-10-02	Black Titan's ordinary shares commenced trading on the Nasdaq stock exchange under the ticker symbol NASDAQ: BTTC.
2025-10-06	Black Titan announced plans to seek long-term strategic crypto initiatives.
2025-10-30	Black Titan entered into a Settlement Agreement with Armistice Capital Master Fund Ltd. for the repurchase of a warrant.
2025-11-10	Shang Ju (Czhang) Lin served as Co-Chief Executive Officer of Black Titan Corporation.
2025-11-28	Date of this Annual Report on Form 20-F.

Recommendation

hold

The company has completed a significant merger and achieved a Nasdaq listing, providing a platform for growth. TalenTec, the core operating entity, demonstrates strong revenue and net income growth in a high-growth Human Capital Management (HCM) market, coupled with strategic plans for regional expansion and cloud-based solutions. However, the new parent company, Black Titan, is nascent with initial losses and working capital deficits, relying on shareholder support. Significant risks include intense competition, dependency on a few key customers and third-party vendors, and identified material weaknesses in internal controls. The new cryptocurrency strategy introduces additional, potentially high-risk, ventures. A 'hold' recommendation is appropriate as the growth potential is balanced by substantial operational and financial risks, warranting close monitoring of integration, risk mitigation, and execution of strategic initiatives before a stronger stance can be taken.

Keywords

Human Capital Management, HCM Solutions, SEC Filing, Merger, Nasdaq Listing, TalenTec, Black Titan, Cloud Computing, Digital Transformation, Artificial Intelligence HR, APAC Market, Cryptocurrency Strategy, Financial Reporting, Corporate Governance, Risk Factors, Software Distribution, Implementation Services, SaaS Subscriptions, Malaysia, Singapore

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.